Thus, boosting the immune response to solid tumors is crucial for improving ICI treatment efficacy.[47, 48, 49] Our results reveal that YY2 overexpression triggers pyroptosis by inducing chromosome missegregation, which consequently enhances tumor sensitivity to anti‐PD‐L1 therapy in CRC, suggesting a potential combinatorial strategy to improve ICI therapy, especially in MSS CRC. This evidence concerns the gene YY2 and neoplasm.